Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TTK HealthcareBOM:507747 -0.99%72 PS Ratio is 1.71 as of Aug. 05, 2026, which is 3% above its 10-year median of 1.66. GuruFocus rates BOM:507747 with a GF Score™ of 72/100 and a GF Value™ of ₹1,459.69 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 954 Drug Manufacturers companies, TTK Healthcare ranks better than 58.91% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, TTK Healthcare's share price is ₹1036.50.
TTK Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹606.64. Hence, TTK Healthcare's PS Ratio for today is 1.71.
The historical rank and industry rank for TTK Healthcare's PS Ratio or its related term are showing as below:
BOM:507747'
s PS Ratio Range Over the Past 10 Years
Min: 0.67 Med: 1.66 Max: 3.26
Current: 1.77
During the past 13 years, TTK Healthcare's highest PS Ratio was 3.26. The lowest was 0.67. And the median was 1.66.
BOM:507747's PS Ratio is ranked better than 58.91% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.31
vs BOM:507747: 1.77
During the past 12 months, the average Revenue per Share Growth Rate of TTK Healthcare was 7.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 5.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 11.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -0.20% per year.
During the past 13 years, TTK Healthcare's highest 3-Year average Revenue per Share Growth Rate was 18.90% per year. The lowest was -13.10% per year. And the median was 5.90% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
TTK Healthcare PS Ratio Related Terms
TTK Healthcare PS Ratio Historical Data
* Premium members only.
The historical data trend for TTK Healthcare's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, TTK Healthcare's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTK Healthcare PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTK Healthcare's PS Ratio distribution charts can be found below:
* The bar in red indicates where TTK Healthcare's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
TTK Healthcare's Share Price of today is ₹1036.50. TTK Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹606.64.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
TTK Healthcare (BOM:507747) has a PS Ratio of 1.71 as of Aug. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on TTK Healthcare and its competitors. This is near median its historical median of 1.66. Over the past decade, TTK Healthcare's PS Ratio has ranged from 0.67 to 3.26. According to the industry distribution chart, TTK Healthcare ranks #392 out of 954 companies in the Drug Manufacturers industry, placing it in the top 41.1%.
Is TTK Healthcare's PS Ratio too high?
TTK Healthcare's current PS Ratio of 1.71 is near median its 10-year median of 1.66. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 3.26. The Drug Manufacturers industry median PS Ratio is 2.31. TTK Healthcare's value of 1.71 is 26% below this industry median. Based on the distribution chart, TTK Healthcare ranks #392 out of 954 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, TTK Healthcare has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTK Healthcare's PS Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, TTK Healthcare ranks #392 out of 954 companies for PS Ratio. This puts TTK Healthcare in the upper half of its industry. The industry median PS Ratio is 2.31. TTK Healthcare's value of 1.71 is 26% below this benchmark. Historically, TTK Healthcare's own PS Ratio has ranged from 0.67 to 3.26 over the past decade. While the company's 10-year median is 1.66 vs. the industry median of 2.31, TTK Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.31, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTK Healthcare's current PS Ratio of 1.71 is 26% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on TTK Healthcare and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTK Healthcare's current PS Ratio is 1.71, which is near median its own 10-year median of 1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTK Healthcare stock overvalued right now?
Based on GuruFocus' analysis, TTK Healthcare (BOM:507747) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,459.69, compared to a current price of ₹1,036.50 — trading 29% below its estimated fair value. The current PS Ratio is 1.71, which is near median its 10-year median of 1.66 and 26% below the Drug Manufacturers industry median of 2.31. TTK Healthcare's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For TTK Healthcare (BOM:507747), the current PS Ratio is 1.71 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTK Healthcare (BOM:507747) Overvalued in 2026?
Based on GuruFocus' analysis, TTK Healthcare stock appears to be undervalued.
The current stock price of ₹1,036.50 is trading 29% below its estimated GF Value™ of ₹1,459.69.
GuruFocus considers TTK Healthcare to be Modestly Undervalued.
Key valuation signals for BOM:507747:
PS Ratio: 1.71 (near median its 10-year median of 1.66)
GF Value™: ₹1,459.69 vs. price of ₹1,036.50 (29% below fair value)
Industry Position: 26% below the Drug Manufacturers median (#392 of 954)
No single metric tells the full story. See the BOM:507747 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTK Healthcare Ltd is an Indian pharmaceutical company. The company's operating segment includes Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods Division, and Others. Its Animal Welfare segment includes products for both Human and Veterinary use. The Consumer Products comprises of marketing and distribution of Woodwards's Gripe Water, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners and others. Protective Devices comprises of manufacturing and marketing of Male Contraceptives and other allied products. It generates maximum revenue from the Pharmaceuticals segment. Geographically, it derives a majority of revenue from India.
72GF Score
Get the complete analysis for BOM:507747
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:507747 has been successfully added to your 
